Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
40 participants
INTERVENTIONAL
2024-03-01
2025-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Green Tea on Cardiometabolic Outcomes
NCT06795438
Effects of Peppermint Oil in Cardiometabolic Outcomes
NCT05071833
Palmitic Acid and Human Microvascular Function
NCT06683534
Effect of Quercetin Supplements on Healthy Males: a Four-Week Randomized Cross-Over Trial
NCT01881919
Biological Effects of Quercetin in COPD Phase II
NCT06003270
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Quercetin tablets 400mg 1 x p/d
Quercetin tablets 400mg 1 x p/d
Quercetin
Quercetin tablets 500mg 1 x per day
Placebo
Placebo
Placebo control 1 x blinded placebo tablet per day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Quercetin
Quercetin tablets 500mg 1 x per day
Placebo
Placebo control 1 x blinded placebo tablet per day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Between 18 \& 65 years
* Non-smoker
* BMI \< 30
* Able to give informed consent
Exclusion Criteria
* Diabetes or any other metabolic/ uncontrolled hypertensive conditions
* Food allergies to quercetin
* Habitual consumption of quercetin
* Not regularly taking medication or antioxidant supplements
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Central Lancashire
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jonathan Sinclair
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Central Lancashire
Preston, Lancashire, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Quercetin cardiometabolic
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.